Suggested remit: To appraise the clinical and cost effectiveness of vutrisiran within its marketing authorisation for treating transthyretin amyloidosis with cardiomyopathy ...

This licence allows individuals, commercial organisations and non-commercial organisations to reuse NICE content free of charge in their publications, products and systems. It applies to requests to ...

A list of downloadable documents created during development.

NICE Pathways offer an easy-to-use, intuitive way of accessing our clinical, public health and social care information. They include up to date NICE guidance, quality standards and related information ...

For further information on the guideline development process, please see how we develop NICE guidelines ...

Proposals for a phased launch of the obesity injection tirzepatide have been set out, as a consultation begins. NHS England ...

A list of downloadable documents created during development.

Empagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal) TA1006 12 September 2024 12 September 2024 Evinacumab for treating homozygous familial hypercholesterolaemia ...

Latanoprost–netarsudil is recommended as an option for reducing intraocular pressure (IOP) in adults with primary open-angle glaucoma or ocular hypertension when a prostaglandin analogue alone has not ...

Section 7 of the National Institute for Health and Care Excellence (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 requires integrated care ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee D. Committee members are asked to declare any interests in the technology being ...